Development of an Industrial Reference Sample for the Specific Activity of Erythropoietin


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

On the basis of WHO recommendations and the principles developed for the standardization of erythropoietins we selected one epoetin alfa pharmaceutical substances included in the State Register of Medicines as a candidate reference sample. The results of the manufacturer’s monitoring of this pharmaceutical substance complied with the requirements of the normative documentation and additional verification of identity by capillary zone electrophoresis demonstrated the presence of eight isoforms, which corresponded to the requirements of the European Pharmacopeia. Conditions for the preparation of an industrial reference sample in lyophilized form were developed. The industrial reference sample was attested in interlaboratory tests and the value of the attested property - specific activity - was 2400 IU/ampule, with confidence limits of 94.5% to 105.8%. Studies of the stability of the industrial reference sample developed here gave a shelf life of five years at a storage temperature of -20°C, with potential to extend this on the basis of stability monitoring results.

Sobre autores

A. Yakovlev

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Autor responsável pela correspondência
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

R. Volkova

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

L. Simutenko

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

E. Postnova

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

T. Batuashvili

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

A. Voropaev

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

N. Alpatova

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

V. Tomilin

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

E. Mytsa

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

V. Bondarev

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

V. Merkulov

Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation

Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2018